Gapping up
News:
- PPBT +61.8% (final results from the randomized Phase 2 study of its lead oncology drug, CM24)
- PTCT +18.5% (Enters into a Global License and Collaboration Agreement with Novartis for PTC518 Huntington's Disease Program)
- NBIS +17.7% (entered into definitive agreements for a $700 million private placement financing)
- OLMA +13% (new clinical trial collaboration and supply agreement with Novartis in frontline metastatic breast cancer)
- RDHL +11.6% (awarded a judgment of approximately $8 million plus costs in a summary judgment by the New York Supreme Court in its legal proceedings against Kukbo Co)
- MRUS +6.8% (Publication of an Abstract on Petosemtamab as 2L+ treatment of r/m HNSCC at the ESMO Asia Congress 2024)
- SMHI +4.8% (announces complete debt refinancing, newbuild orders, and vessel sales)
- XPEV +4.1% (November deliveries)
- AITR +3.2% (terminates business combination agreement with American Metals LLC)
- ZK +2.9% (November deliveries)
- API +2.9% (enters voluntary lock-ups by senior management)
- AUTL +2.4% (publication of data from the FELIX study of obe-cel in r/r Adult B-ALL patients in The New England Journal of Medicine)
- IHS +0.9% (signs agreement to sell Kuwait Operations to Zain Group)
- WYNN +0.8% (Macau revs)